Literature DB >> 19321509

Oral nystatin prophylaxis and neonatal fungal infections.

A Howell1, D Isaacs, R Halliday.   

Abstract

BACKGROUND: The value of antifungal prophylaxis depends partly on the incidence of neonatal fungal infection. We compared the incidence of fungal infection in babies in neonatal units which do and do not give antifungal prophylaxis using oral nystatin.
METHODS: Prospective, multi-centre surveillance study from 1993 to 2006 of invasive fungal infection, defined as positive blood or cerebrospinal fluid culture, in babies <1500 g birth weight in neonatal units in Australia and New Zealand.
RESULTS: There were 118 episodes of invasive fungal infection in 14 778 babies <1500 g, an incidence of 0.80% (95% confidence interval (CI) 0.66 to 0.94%). All infections were due to Candida species, mostly C. albicans (74, 62.7%) and C. parapsilosis (39, 33.1%). The mortality was 16.5%. The incidence was 0.54% (0.38 to 0.70%) for babies <1500 g in units using selective or universal oral nystatin prophylaxis and 1.23% (0.84 to 1.62%) in units using no prophylaxis (p<0.001). The incidence of infection in babies <1000 g was 1.78% (106/5948) (95% CI 1.44 to 2.12%). The incidence was 1.23% (0.92 to 1.54%) for babies <1000 g in units using nystatin prophylaxis and 2.67% (1.97 to 3.37%) in units using no prophylaxis (p<0.001).
CONCLUSIONS: The incidence of neonatal fungal infection was low in Australia and New Zealand, even without antifungal prophylaxis. Antifungal prophylaxis with oral nystatin was associated with a significantly lower incidence of fungal infection compared with no prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19321509     DOI: 10.1136/adc.2008.157123

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  15 in total

Review 1.  Prophylactic oral/topical non-absorbed antifungal agents to prevent invasive fungal infection in very low birth weight infants.

Authors:  Nicola Austin; Jemma Cleminson; Brian A Darlow; William McGuire
Journal:  Cochrane Database Syst Rev       Date:  2015-10-24

2.  Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis.

Authors:  Rachel G Greenberg; Daniel K Benjamin; Marie G Gantz; C Michael Cotten; Barbara J Stoll; Michele C Walsh; Pablo J Sánchez; Seetha Shankaran; Abhik Das; Rosemary D Higgins; Nancy A Miller; Kathy J Auten; Thomas J Walsh; Abbot R Laptook; Waldemar A Carlo; Kathleen A Kennedy; Neil N Finer; Shahnaz Duara; Kurt Schibler; Richard A Ehrenkranz; Krisa P Van Meurs; Ivan D Frantz; Dale L Phelps; Brenda B Poindexter; Edward F Bell; T Michael O'Shea; Kristi L Watterberg; Ronald N Goldberg; P Brian Smith
Journal:  J Pediatr       Date:  2012-03-15       Impact factor: 4.406

Review 3.  Does the use of oral nonabsorbable antifungal prophylaxis reduce the incidence of fungal colonization and/or systemic infection in preterm infants?

Authors:  Russell A Lam; Kimberly E Dow
Journal:  Paediatr Child Health       Date:  2013-03       Impact factor: 2.253

4.  Dietary Supplementation With Medium-Chain Triglycerides Reduces Candida Gastrointestinal Colonization in Preterm Infants.

Authors:  Amanda B Arsenault; Kearney T W Gunsalus; Sonia S Laforce-Nesbitt; Lynn Przystac; Erik J DeAngelis; Michaela E Hurley; Ethan S Vorel; Richard Tucker; Nirupa R Matthan; Alice H Lichtenstein; Carol A Kumamoto; Joseph M Bliss
Journal:  Pediatr Infect Dis J       Date:  2019-02       Impact factor: 2.129

Review 5.  Challenges in developing a consensus definition of neonatal sepsis.

Authors:  Matthew McGovern; Eric Giannoni; Helmut Kuester; Mark A Turner; Agnes van den Hoogen; Joseph M Bliss; Joyce M Koenig; Fleur M Keij; Jan Mazela; Rebecca Finnegan; Marina Degtyareva; Sinno H P Simons; Willem P de Boode; Tobias Strunk; Irwin K M Reiss; James L Wynn; Eleanor J Molloy
Journal:  Pediatr Res       Date:  2020-03-03       Impact factor: 3.756

6.  Prophylactic Saccharomyces boulardii versus nystatin for the prevention of fungal colonization and invasive fungal infection in premature infants.

Authors:  Gamze Demirel; Istemi Han Celik; Omer Erdeve; Sibel Saygan; Ugur Dilmen; Fuat Emre Canpolat
Journal:  Eur J Pediatr       Date:  2013-05-24       Impact factor: 3.183

Review 7.  Candida parapsilosis is a significant neonatal pathogen: a systematic review and meta-analysis.

Authors:  Mohan Pammi; Linda Holland; Geraldine Butler; Attila Gacser; Joseph M Bliss
Journal:  Pediatr Infect Dis J       Date:  2013-05       Impact factor: 2.129

8.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

Review 9.  Efficacy of nystatin for the treatment of oral candidiasis: a systematic review and meta-analysis.

Authors:  Xin Lyu; Chen Zhao; Zhi-Min Yan; Hong Hua
Journal:  Drug Des Devel Ther       Date:  2016-03-16       Impact factor: 4.162

10.  Oral candidiasis in HIV-uninfected pediatric population in areas with limited fungal diagnosis: A case study from a tertiary hospital, Tanzania.

Authors:  Martha F Mushi; Neema Loi; Stephen E Mshana
Journal:  Ther Adv Infect Dis       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.